A Phase I/II Dose-escalation and Dose-expansion Study to Evaluate the Safety and Efficacy of FT-002 Subretinal Injection in Subjects With RPGR Gene Mutation-associated X-linked Retinitis Pigmentosa.

The aim of this study was to evaluate the safety, tolerability, and efficacy of one-time subretinal injection of FT-002 in male subjects (8-45 years of age) with RPGR (Retinitis Pigmentosa GTPase Regulator) gene mutation-associated X-linked retinitis pigmentosa, of XLRP. This study includes Phase I (dose escalation phase) and Phase II (dose expansion phase).

开始日期2024-04-01

申办/合作机构

Frontera Therapeutics, Inc.

NCT06492876

/ Recruiting临床1/2期

A Dose-escalation and Dose-expanded Phase I/II Clinical Study to Evaluate the Safety, and Efficacy of FT-003 in Subjects With DME

The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of disposable vitreous injection of FT-003 in subjects with Diabetic Macular Edema (DME). The study was divided into two phases, Phase 1 dose escalation and Phase II dose expansion.

开始日期2023-11-15

申办/合作机构

Frontera Therapeutics, Inc.

NCT06492863

/ Recruiting临床1/2期

A Dose-escalation and Dose-expanded Phase I/II Clinical Study to Evaluate the Safety, and Efficacy of FT-003 in Subjects With Wet AMD

The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of disposable vitreous injection of FT-003 in subjects with neovascular age-related Macular Degeneration (nAMD). The study was divided into two phases, Phase 1 dose escalation and Phase II dose expansion.

开始日期2023-08-15

申办/合作机构

Frontera Therapeutics, Inc.

[+3]

100 项与 Frontera Therapeutics, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Frontera Therapeutics, Inc. 相关的专利（医药）

登录后查看更多信息

492

项与 Frontera Therapeutics, Inc. 相关的新闻（医药）

2025-08-07

·同写意

乐普生物发布2025年度上半年正面盈利预告丨会员动态

抗体药物偶联物申请上市

2025-08-06

·同写意

长风药业吸入小核酸药物研发子公司入驻BioBAY！ | 会员动态

siRNA核酸药物

2025-08-06

·同写意

北京中健云康成为大兴临空区首个GSP药械双证企业 | 会员动态

核酸药物引进/卖出

100 项与 Frontera Therapeutics, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Frontera Therapeutics, Inc. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2025年08月12日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

临床申请批准

临床2期

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

FT-001(Frontera) ( RPE65 )	2型利伯先天性黑朦症更多	临床2期
FT-003	糖尿病性黄斑水肿更多	临床1/2期
FT-004 ( factor IX )	血友病B 更多	临床1/2期
FT-002 ( RPGR )	X连锁视网膜色素变性更多	临床1/2期
FT-017 ( MYBPC3 )	肥大型心肌病更多	临床申请批准